文献速递肿瘤 PET/CT放射性药物与辐射防护

18F-BMS-986192 PET预测NSCLC纳武利尤单抗持久缓解

18F-BMS-986192 PET to Predict Durable Response to Nivolumab in NSCLC: A Novel Approach Beyond PD-L1 Immunohistochemistry.
PubMed 文献 · J Nucl Med · 2026-10-29

这项前瞻性多中心生物标志物探索研究纳入91例IV期非小细胞肺癌患者,最终77例分析18F-BMS-986192 PET/CT。PD-L1免疫组化在PFS<9月与≥9月组间无差异,而肺病灶PD-L1 PET摄取在PFS≥9月组显著更高(P=0.01)。以mean SUVpeak 2.4为阈值,PD-L1 PET对持久临床获益的阴性预测值达94%,且与PFS和OS显著相关。

要点

  • PD-L1免疫组化未能区分PFS<9月与≥9月患者,而PD-L1 PET摄取在PFS≥9月组显著更高。
  • 以mean SUVpeak 2.4为阈值,PD-L1 PET对持久临床获益的阴性预测值为94%。
  • PD-L1 PET摄取与18F-FDG摄取无相关性。

核心结论

  • 18F-BMS-986192 PET/CT显示患者间PD-L1表达存在差异,肺病灶低摄取以高阴性预测值预测不良结局。
  • 在本队列中,18F-BMS-986192 PET/CT的阴性预测值优于基线PD-L1免疫组化。
  • 上述发现需前瞻性验证。

研究设计与样本

  • 前瞻性多中心生物标志物探索研究,纳入适合纳武利尤单抗治疗的IV期非小细胞肺癌患者。
  • 治疗前进行基线18F-BMS-986192 PET/CT、18F-FDG PET/CT及肿瘤活检PD-L1免疫组化。
  • 主要终点为持久临床获益,定义为无进展生存期(PFS)≥9个月。
  • 91例入组患者中77例纳入18F-BMS-986192 PET/CT最终分析。

主要发现

  • PD-L1免疫组化在PFS<9月与≥9月患者间无差异。
  • 肺病灶PD-L1 PET摄取在PFS≥9月患者中显著更高(P=0.01)。
  • 以mean SUVpeak 2.4为最佳截断值,PD-L1 PET对持久临床获益的阴性预测值为94%。
  • PD-L1 PET摄取与PFS和总生存期均显著相关,尤其在一线治疗患者中。
  • 示踪剂摄取与18F-FDG摄取无相关性。

关键数值与推荐

  • 持久临床获益定义为PFS≥9个月。
  • PD-L1 PET最佳mean SUVpeak截断值为2.4。
  • 该截断值下PD-L1 PET对持久临床获益的阴性预测值为94%。

临床怎么用

  • 18F-BMS-986192 PET/CT可无创评估全肿瘤PD-L1表达及异质性。
  • 肺病灶低摄取提示免疫治疗结局不良,可辅助识别可能缺乏持久获益的患者。

局限性

  • 研究为生物标志物探索性分析,最终分析仅纳入77例患者。
  • 作者指出上述发现需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Programmed death ligand 1 (PD-L1) immunohistochemistry, the current standard biomarker for predicting response to programmed death protein 1/PD-L1 checkpoint inhibitors in non-small cell lung cancer, has moderate predictive value among others because of tumor heterogeneity and limited biopsy representation, whereas PD-L1 PET/CT using 18F-BMS-986192 enables noninvasive, whole-tumor assessment of PD-L1 expression and heterogeneity, potentially improving prediction of response to immunotherapy. Methods: In this prospective multicenter biomarker exploration study, patients with stage IV non-small cell lung cancer eligible for nivolumab-based therapies underwent baseline 18F-BMS-986192 PET/CT, 18F-FDG PET/CT, and tumor biopsy for PD-L1 immunohistochemistry before treatment initiation. The primary endpoint was durable clinical benefit, defined as progression-free survival (PFS) of 9 mo or greater, with secondary analyses assessing associations among tracer uptake, PD-L1 expression, survival outcomes, and PET-based radiomic features. Results: Of 91 enrolled patients, 77 were included in the final analysis of 18F-BMS-986192 PET/CT. Although PD-L1 immunohistochemistry did not differ between patients with PFS of less than 9 mo versus 9 mo or greater, PD-L1 PET uptake in lung lesions was significantly higher in patients with PFS of at least 9 mo (P = 0.01). Using an optimal mean SUVpeak cutoff of 2.4, PD-L1 PET demonstrated a high negative predictive value (94%) for durable clinical benefit, with significant associations for both PFS and overall survival, particularly in patients receiving first-line treatment. Tracer uptake showed no correlation with 18F-FDG uptake. Conclusion: 18F-BMS-986192 PET/CT revealed interpatient PD-L1 variability. Low uptake in lung lesions predicted poor outcomes with high negative predictive value. 18F-BMS-986192 PET/CT demonstrated stronger negative predictive value than did baseline PD-L1 immunohistochemistry in this cohort. These findings require prospective validation.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Borm FJ, Smit J, Gerards NR, et al. 18F-BMS-986192 PET to Predict Durable Response to Nivolumab in NSCLC: A Novel Approach Beyond PD-L1 Immunohistochemistry. J Nucl Med. 2026. PMID: 42957208. doi:10.2967/jnumed.126.272588

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。